China Shineway Pharmaceutical Group Limited
CSWYY
Other OTC19.25
USD
- -
- -
ISIN
US16947J1007
CUSIP
16947J100
Return %
Stock
S&P500
1Y
- -
19.25
3Y
2.39
65.11
5Y
-13.01
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zhenjiang Li
- Full Time Employees
- 2,822
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- No. 168 Shiluan Street Shijiazhuang HE People's Republic of China 051430
- IPO Date
- Feb 14, 2012
- Website
- shineway.com.hk
- Similar Companies
- Business
- China Shineway Pharmaceutical Group Limited is an investment holding company primarily engaged in the research, development, manufacturing, and trading of traditional Chinese medicines and modern pharmaceuticals. The company’s product portfolio includes injections, soft capsules, granules, tablets, pills, oral liquids, powders, and traditional Chinese medicine granules across multiple therapeutic areas such as respiratory system diseases, cardiovascular and cerebrovascular conditions, nervous system disorders, digestive system diseases, orthopedics, pediatrics, and general body strengthening medications. Key products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, and Compound Licorice Tablet. China Shineway also engages in the trading of agricultural products related to its pharmaceutical operations. Founded in 1997 and headquartered in Shijiazhuang, People's Republic of China, the company operates primarily in Mainland China and Hong Kong, with increasing international sales contributing to approximately 15% of total revenue. It conducts sales through direct hospital and clinic partnerships, distributor networks, and retail pharmacies, aiming to expand into Southeast Asian markets. In the last 1-2 years, China Shineway has enhanced its R&D capabilities by investing RMB 200-300 million annually, focusing on innovative drug development and production technologies. The company has recently formed strategic collaborations with research institutions such as Yunnan University of Chinese Medicine and TCM hospitals to promote clinical applications of traditional Chinese medicine granules and conduct comparative efficacy studies. Additionally, it pursues growth through expanding its product portfolio, including over 100 registered pharmaceutical products, and has maintained operational efficiency with improving gross margins. These efforts align with its strategic ambition to foster innovation and penetrate new markets domestically and internationally. China Shineway operates through key business segments covering pharmaceuticals, healthcare products, and R&D, positioning itself as a leader in the traditional Chinese medicine sector with a significant market share of approximately 35% in that niche. It remains committed to maintaining steady revenue growth, with recent figures indicating a turnover near CN¥3.34 billion and net profits reflecting a strong financial foundation. The company is publicly listed on the Hong Kong Stock Exchange under the ticker 2877.HK and is a subsidiary of BH Corporate Services Ltd.